m+Medelevator.RU
← Поиск публикаций
Disability and rehabilitation · 2026

The effects of ankle-foot orthoses on the gait of people with multiple sclerosis: a systematic review and meta-analysis.

СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Mosharaf Mahshid, Saberi Shirin, Hillier Susan, Sadeghi-Demneh Ebrahim

Аннотация

PURPOSE: To systematically review and quantify the effects of ankle-foot orthoses (AFOs) on gait in people with multiple sclerosis (PwMS).

MATERIALS AND METHODS: PubMed, Scopus, and Web of Science were searched to 27 September 2025. Randomized controlled, crossover, and before-and-after clinical trials assessing AFOs on gait in PwMS were included. Outcomes comprised temporospatial, kinematic, kinetic, functional mobility, energy cost, fatigue, and balance measures. Two reviewers independently screened studies, extracted data, and assessed risk of bias. Meta-analyses were performed where feasible; other outcomes were synthesized narratively.

RESULTS: Sixteen studies (n = 261) were included. Meta-analysis found no significant effects on walking speed, cadence, stride length, or 6-min walk distance. However, ankle range of motion increased significantly (MD = 12.69°; 95% CI: 2.86 to 22.52; p < 0.001). Subgroup analysis suggested dynamic AFOs could improve 6-min walk distance compared to static AFOs (MD = 45.82 m; 95% CI: 26.93 to 64.71), while comparisons with functional electrical stimulation showed no differences.

CONCLUSIONS: AFOs improve specific biomechanical deficits (e.g. ankle motion) in PwMS, and dynamic designs may enhance endurance. Effects on core gait parameters are inconsistent, and the evidence is limited and heterogeneous. Clinical prescriptions should be individualized, and larger, high-quality trials are needed to inform guidelines.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты